微生物与感染
2025年1月9日 星期四   首页 |  主编心语 |  期刊介绍 |  编委阵容 |  投稿指南 |  出版道德 |  期刊订阅 |  联系我们 | English
微生物与感染  2023, Vol. 18 Issue (1): 35-45    DOI: 10.3969/j.issn.1673-6184.2023.01.005
  综述 本期目录 | 过刊浏览 | 高级检索 |
乙型肝炎核心相关抗原的分子基础与临床应用
章申琰*,沈忠良*,张继明
复旦大学附属华山医院感染科,上海市传染病与生物安全应急响应重点实验室,国家传染病医学中心,上海 200040
Molecular basis and clinical application of hepatitis B core-related antigen
ZHANG Shenyan*,SHEN Zhongliang*,ZHANG Jiming
Department of Infectious Diseases of Huashan Hospital, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Fudan University, Shanghai 200040, China
全文: PDF (1100 KB)   HTML (225)
输出: BibTeX | EndNote (RIS)      
摘要: 作为新近发现的血清学标志物,乙型肝炎核心相关抗原(Hepatitis B core-related antigen, HBcrAg)由乙型肝炎核心抗原(Hepatitis core antigen, HBcAg)、乙型肝炎e抗原(Hepatitis e antigen, HBeAg)、p22cr组成。血清HBcrAg可反映肝内共价闭合环状DNA的水平及转录活性,并在一定程度上预测慢性乙型肝炎(简称乙肝)患者自然转归或核苷(酸)类似物、干扰素的疗效与预后,包括复发、功能性治愈等临床结局的发生率等,从而为临床抗病毒治疗起点与终点的确定、治疗方案的选择提供指导。同时,HBcrAg水平与乙肝相关的肝细胞肝癌(Hepatocellular carcinoma, HCC)的发生率亦有关联,可识别潜在的HCC高危患者。因此,HBcrAg在慢性乙肝诊治中有着重要的临床应用价值。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
章申琰*
沈忠良*
张继明
关键词 乙型肝炎核心相关抗原慢性乙型肝炎抗病毒治疗肝细胞肝癌    
Abstract:As a recently discovered serological marker, hepatitis B core-related antigen (HBcrAg) consists of hepatitis B core antigen (HBcAg), hepatitis B e antigen (HBeAg) and p22cr. Serum HBcrAg can reflect the level and transcriptional activity of intrahepatic covalently closed circular DNA, as well as predict the natural history of patients with chronic hepatitis B or the efficacy and prognosis of nucleos(t)ide analogues and interferons, including the incidence of clinical outcomes such as relapse and functional cure, thus providing guidance for the determination of the starting point and endpoint of clinical antiviral therapy and the selection of treatment regimens. HBcrAg levels are also associated with the incidence of HBV-associated hepatocellular carcinoma(HCC), which can identify potential high-risk patients for HCC. Therefore, HBcrAg has important clinical application value in the diagnosis and treatment of chronic hepatitis B.
Key wordsHepatitis B core-related antigen    Chronic hepatitis B    Antiviral treatment    Hepatocellular carcinoma 
ZTFEL:  R512.6+2  
  R446.6  
基金资助:国家自然科学基金(82172255),上海市启明星计划(20QA1401800)
通讯作者: 张继明   
引用本文:   
章申琰*,沈忠良*,张继明. 乙型肝炎核心相关抗原的分子基础与临床应用[J]. 微生物与感染, 2023, 18(1): 35-45.
ZHANG Shenyan*,SHEN Zhongliang*,ZHANG Jiming. Molecular basis and clinical application of hepatitis B core-related antigen. JOURNAL OF MICROBES AND INFECTIONS, 2023, 18(1): 35-45.
链接本文:  
http://jmi.fudan.edu.cn/CN/10.3969/j.issn.1673-6184.2023.01.005     或     http://jmi.fudan.edu.cn/CN/Y2023/V18/I1/35

版权所有 © 2008 《微生物与感染》编辑部
地址:上海市医学院路138号 邮编:200032
Tel:021-54237633 Fax:021-64434224    E-mail:jmi@fudan.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发  技术支持:support@magtech.com.cn